TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03064074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
Study: NCT00413439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Intravenous solution or oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Intravenous solution or oral capsules
Study: NCT03465527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrednisoLONE 50 MG
Description: Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Study: NCT01239758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 1 from core study, A031-03)
Description: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 2 from core study, A031-03)
Description: Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 3 from core study, A031-03)
Description: Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
Study: NCT04504786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitality acupunch (VA) exercise program
Description: The VA had three phases and took 40 minutes to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintained their daily activities.
Study: NCT03176654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVLAT manipulation
Description: HVLAT will be performed 10 minutes after the first blood draw.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham HVLAT manipulation
Description: Sham HVLAT will be performed 10 minutes after the first blood draw.
Study: NCT03504423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613, mFolfirinox
Description: CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: Folfirinox
Study: NCT00985023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable screw fixation of Lisfranc fracture-dislocations.
Description: Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
Study: NCT01340612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coiling with any type of currently approved coil (first or second generation)
Description: Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
Study: NCT01424397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP
Description: 200ug intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: 200ug intranasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo intranasal
Study: NCT04364139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal less than or equal to 92 mm Hg
Description: Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal less than or equal to 92 mm Hg
Description: Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal less than or equal to 92 mm Hg
Description: Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal 102-107 mm Hg
Description: Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal 102-107 mm Hg
Description: Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal 102-107 mm Hg
Description: Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
Study: NCT01294215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Description: Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
Study: NCT01808339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Description: Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Description: Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
Study: NCT04981158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (Epidural /GA using tolerable endotracheal tube (TET) group, group II
Description: patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard general anesthetic technique, control group, group I
Description: patients will undergo standard general anesthesia with classic endotracheal tube
Study: NCT01933802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intrathecal administration of autologous MSC-NP
Description: Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
Study: NCT00158782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
Study: NCT01340612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coiling with any type of currently approved coil (first or second generation)
Description: Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.
Description: Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
Study: NCT01483755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneaous intervention
Description: Conventional primary percutaneaous intervention
Study: NCT03562533

Intervention type: DRUG
Intervention: pegylated liposomal doxorubicin (PLD) + carboplatin (CD)
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles

Intervention type: DRUG
Intervention: carboplatin + paclitaxel (CP)
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
Study: NCT04345042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Massage (Swedish Technique)
Description: Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
Study: NCT00791570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT03187275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish Massage Therapy
Description: The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Touch Intervention
Description: The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
Study: NCT02814578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherent tomography
Description: comparative method for BVS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IntraVascular UltraSound
Description: The method of goldstandard for decision stent choice
Study: NCT02197247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - rifampicin
Description: Blood sampling to measure rifampicin levels

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study: NCT01934023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Champix (Varenicline) is an approved smoking cessation medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01267760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multipass hemodialysis
Description: 8-hour dialysis using a recycled dialysis bath of 25-30 l
Study: NCT01676571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: 10 mg immediate-release (IR), one single dose, orally
Study: NCT03069300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Study: NCT01060813

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine supplements
Description: leucine supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine supplements
Description: leucine supplements
Study: NCT03478657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ease of use questionnaires
Description: Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
Study: NCT02983825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP); level changes
Description: as per arm description
Study: NCT00415805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multihance
Description: 0.5 Molar, single injection at 0.2 mL/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasovist
Description: 0.25 molar single injection 0.03 ml/kg
Study: NCT00169546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Study: NCT02479542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gauze Dressing
Description: Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiCare NPWT dressing
Description: Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
Study: NCT00397345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trovax
Description: 1ml IM injection 2-8 weeks apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care therapy
Description: subcutaneous low dose IL-2, interferon-α or sunitinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care therapy
Description: subcutaneous low dose IL-2, interferon-α or sunitinib
Study: NCT01197261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone naloxone prolonged release tablets
Description: 2 tablets/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 2 tablets/ day
Study: NCT01781975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (For imatinib mesylate)
Study: NCT01940601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim 300 ug/kg and Balugrastim 670 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
Study: NCT01887782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFL rTMS
Description: Magventure Cool B70 Coil with either RX100 or RX30 Stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
Study: NCT02585726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SP-402 VenaSeal™ Closure System
Description: A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SP-402 VenaSeal™ Closure System
Description: A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
Study: NCT01940601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim 5 μg/kg
Study: NCT02627521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRU guided CABG
Description: Coronary Artery Bypass Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG per standard of care
Description: Coronary Artery Bypass Surgery
Study: NCT03737422

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 2 capsuls hesperidin and 30 g flaxseed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study: NCT01840228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micronized progesterone suppository
Study: NCT01508494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 16 mg galantamine daily P/O

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo